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ABSTRACT
Several circulating biomarkers and single nucleotide polymorphisms (SNPs) 
have been correlated with efficacy and tolerability to antiangiogenic agents. These 
associations remain unexplored in well-differentiated, metastatic pancreatic 
neuroendocrine tumors treated with the multitargeted tyrosine kinase inhibitor 
sunitinib. We have assessed the effect on tumor response at 6 months, overall survival, 
progression-free survival and safety of 14 SNPs, and 6 soluble proteins. Forty-three 
patients were recruited. Two SNPs in the vascular endothelial growth factor receptor 
3 (VEGFR-3) gene predicted lower overall survival: rs307826 with hazard ratio (HR) 
3.67 (confidence interval [CI] 95%, 1.35-10.00) and rs307821 with HR 3.84 (CI 95%, 
1.47-10.0). Interleukin-6 was associated with increased mortality: HR 1.06 (CI 95%, 
1.01-1.12), and osteopontin was associated with shorter PFS: HR 1.087 (1.01-1.16), 
independently of Ki-67. Furthermore, levels of osteopontin remained higher at the 
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end of the study in patients considered non-responders: 38.5 ng/mL vs. responders: 
18.7 ng/mL, p-value=0.039. Dynamic upward variations were also observed with 
respect to IL-8 levels in sunitinib-refractory individuals: 28.5 pg/mL at baseline vs. 
38.3 pg/mL at 3 months, p-value=0.024. In conclusion, two VEGFR-3 SNPs as well as 
various serum biomarkers were associated with diverse clinical outcomes in patients 
with well-differentiated pancreatic neuroendocrine tumors treated with sunitinib.
INTRODUCTION
Pancreatic neuroendocrine tumors (PNETs) 
represent a heterogeneous group of neoplasms arising 
from pancreatic islets, with an incidence of <2 per 
100 000 persons per year [1]. In the case of well-
differentiated (G1/2), metastatic PNETs, evolution is 
generally indolent compared to adenocarcinoma of the 
pancreas [2]. One of its most salient biological traits is its 
extraordinary vascularization, which is associated with 
the expression of multiple proangiogenic molecules, 
such as vascular endothelial growth factor receptors 
(VEGFR) and platelet-derived growth factor (PDGF) or 
fibroblast growth factors (FGFs) [3]. The overexpression 
or activation of proangiogenic pathways (e.g., 
upregulation of hypoxia-response transcription factors, 
genes of cellular response to hypoxia, the VEGF/VEGFR 
axis and crosstalk between pericytes and endothelial 
cells involving VEGF and PDGF) promotes growth in 
PNETs by directly upregulating angiogenesis, in addition 
to other indirect mechanisms [4, 5]. Additionally, the 
phosphatidilinositol-3-kinase (PI3K)-AKT-mTOR 
(mammalian target of rapamycin) pathway acts as the 
central hub for several cell programs in PNETs, including 
the participation in complex crosstalk regulating VEGF 
synthesis [6]. Indeed, the use of mTOR inhibitors is able 
to prolong progression-free survival (PFS) in advanced 
PNETs [7].
Among the angiogenesis inhibitors tested in PNETs, 
sunitinib malate (Sutent, Pfizer) is an oral, multitargeted 
tyrosine kinase inhibitor (TKI) primarily targeting 
VEGFR-1, VEGFR-2, VEGFR-3, RET,stem-cell factor 
receptor (c-kit), and PDGFR-α/β. In the SUN-1111 study, 
a phase III clinical trial in patients with well-differentiated 
PNETs in progression, sunitinib 37.5 mg/day increased 
PFS compared to placebo (11.4 versus 5.5 months; hazard 
ratio [HR], 0.42; p<0.001), with an objective response 
rate of 9.3% and a favorable safety profile [8]. Certain 
germline single-nucleotide polymorphisms (SNPs) in 
VEGFR-3, VEGFA, interleukin-8 (IL-8), FGFR2, c-KIT, 
or PDGFB have been correlated with clinical outcomes in 
subjects receiving sunitinib [9, 10]. In addition, various 
SNPs in genes that participate in metabolic pathways, 
efflux transporters and cell detoxification, such as ATP-
binding cassette sub-family B member 1 (ABCB1), 
Nuclear Receptor Subfamily 1 Group I Member 2 (NR1I2) 
and cytochrome P450 (CYP3A5), might be associated 
with its therapeutic efficacy or toxicity [9, 11]. However, 
no subgroup effect was noted in the SUN-1111 trial and, 
consequently, to date, no validated biomarker has been 
able to be incorporated into clinical practice for use in 
PNETs.
Furthermore, this high angiogenic profile is 
associated with the secretion of a repertoire of soluble 
molecules (e.g., proangiogenic cytokines and growth 
factors) that might be predictive biomarkers involved in 
the development of resistance to antiangiogenic drugs 
[12, 13].
In this situation, we have designed a prospective, 
multicenter study (Search activity in the laboratory for 
sunitinib, SALSUN) to identify biomarkers and SNPs 
involved in the efficacy or tolerability of sunitinib in 




Forty-three patients treated between November 
2012 and February 2015 were recruited; the follow-up 
database was closed in October 2017. All were evaluable 
for efficacy and safety endpoints, although SNPs were 
not available for two patients. Patients’ baseline clinical 
characteristics are summarized in Table 1. In particular, 
sunitinib was administered as first-line treatment in 
41.9% (n=18), as second-line in 34.9% (n=15), and as 
successive lines in the remaining subjects. The starting 
dose of sunitinib was 37.5 mg per day. Subjects remained 
on treatment with sunitinib for a median of 6.3 months 
(range, 0.2-29); at six months, 37% of them (n=16) had 
discontinued treatment: 56.3% (n=9) due to progression, 
18.8% (n=3) because of toxicity, and the remaining 25.0% 
(n=4) for another reason. The median follow-up was 51.3 
months (95% confidence Interval [CI]), 44.2-58.3). In the 
population evaluable for efficacy endpoints (n=43), 40 
progression events (93%) were detected and median PFS 
was 12.0 months (95% CI, 7.2-16.7). Moreover, 40 deaths 
(93%) were recorded with a median OS of 53.5 months 
(95% CI, 45.4-61.6).
As for the objective response rate at 6 months 
(n=41), no patient attained a full response; 6 (14.6%) 
exhibited partial response; 30 (73.2%) displayed 
stable disease, and 5 individuals (12.2%) progressed. 
Consequently, the rate of clinical benefit was 87.8% 
(n=36). In the population suitable for analysis for safety 
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Table 1: Baseline characteristics of the patients
Patients, N=43
Sex (female) 20 (46.5%)
Age (median, range) 56 (28-77)*
ECOG-PS
 0 24 (55.8%)
 1 19 (44.2%)
Location of the tumor
 Head 12 (27.9%)
 Head and body 1 (2.3%)
 Tail 16 (37.2%)
 Tail and body 4 (9.3%)
 Body 2 (4.6%)
 NR 6 (13.9%)
Tumor stage
 Locally advanced 1 (2.3%)
 Metastatic 42 (97.7%)
Number of metastatic locations
 1 22 (51.1%)
 2 15 (34.8%)
 3 1 (2.3%)
 4 3 (6.9%)
 NR 2 (4.6%)
Metastatic locations
 Lung 1 (2.3%)
 Nodes 13 (30.2%)
 Bone 4 (9.3%)
 Liver 40 (93.0%)
 Others 5 (11.6%)
Functioning tumor 6 (13.9%)
Concurrent SSA 19 (44.1%)
Prior treatments
 None 18 (41.8%)
 SSA 13 (30.2%)
 Chemotherapy 6 (13.9%)
 SSA and chemotherapy 5 (11.6%)
 SSA and radiotherapy 1 (2.3%)
Ki-67 index 
 <3 9 (20.9%)
 3-10 16 (37.2%)
 11-20 12 (27.9%)
 NR 6 (13.9%)
The percentage refers to columns. *The datum for age expresses the median and range. Abbreviations: N = sample size, NR 
= not reported, ECOG-PS = Eastern Cooperative Group Performance Status, SSA = somatostatin analogue.
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endpoints (n=43), the most common grade 1-4 toxicities 
were asthenia (n=31; 72%), diarrhea (n=22; 51%), 
hypothyroidism (n=9; 21%), neutropenia (n=18; 42%), 
hand-foot syndrome (n=13; 30%), arterial hypertension 
(n=13; 30%), and thrombocytopenia (n=8; 19%). There 
was only a single case of grade 4 toxicity (diarrhea). 
Dose reduction due to toxicity was required in 16 patients 
(37%). The breakdown of the severity of these toxicities 
is shown in Supplementary Table 1.
Of the 43 evaluable patients, a sample for 
genotyping SNPs was available for 41 (1 patient was 
randomly lost to follow-up and another sample was 
hemolyzed on receipt). Supplementary Table 2 presents the 
SNPs analyzed and allele frequencies, all of which were 
compatible with the Hardy and Weinberg equilibrium, 
p>0.05. As for circulating biomarkers, blood samples for 
baseline determination were received for 36 of 43 subjects 
(83%); in the remaining cases (n=7), material was not 
available either because there was insufficient blood or 
tubes were missing. At three months, 31 blood samples 
were available (two individuals died before sampling; 
three were missing for purely administrative reasons). At 
the end of the study, we had four additional drop-outs (two 
due to severe clinical impairment, two missing values for 
administrative reasons).
Effect of polymorphisms on the rate of clinical 
benefit, PFS, and OS
Table 2 displays the results of Cox’s PH regression 
for survival endpoints (PFS/OS) and binary logistic 
regression for clinical benefit. Two polymorphisms related 
to angiogenesis were significantly associated with OS: 
VEGFR-3 c.1480A>G (rs307826) with HR 3.67 (CI 95%, 
1.35-10.00), and VEGFR-3 c.4202G>T (rs307821) with 
HR 3.84 (CI 95%, 1.47-10). The wild-type genotype of 
VEGFR-3 was associated with increased median overall 
survival (OS) (49 months; 95% CI, 28-71) compared 
to the 29 months, (CI 95% CI, 8-50) for rs307821 GT/
TT allele variants (Log Rank, p=0.027) (see Figure 1). 
None of the genotypes analyzed were associated with the 
probability of objective response, clinical benefit or PFS 
(Table 2). Insofar as safety data are concerned, the only 
predictive factor associated with a higher percentage of 
dose reductions was the VEGFR-3 rs307826 SNP. Thus, 
the dose was lowered in the first 6 months in 21% of 
the homozygous wild-type subjects vs. 59% in patients 
with the other genotypes; odds ratio (OR) 5.33 (CI 
95%, 1.20-23.65), p=0.027 (see Table 3). Patients with 
variant VEGFR-3 alleles (rs307821) had a higher rate of 
hypothyroidism: 45% vs. 36%, OR 5.41 (CI 95%, 1.10-
26.46), p=0.041. No other SNP was found to be associated 
with toxicity (of any type) or with antiangiogenic 
side effects (Table 3). No differences were detected in 
treatment duration based on the SNPs analyzed. None of 
these tests was significant after applying Holm-Bonferroni 
correction.
Effect of circulating biomarkers on response and 
survival endpoints
Possible temporary, sunitinib-sensitivity dependent 
variations were analyzed (see Table 4). All p-values were 
Holm-Bonferroni corrected. A significant increase was 
noted in IL-8 levels in subjects with progressive disease 
at 3 months: 28.5 pg/mL (interquartile range [IQR], 30.9) 
at baseline vs. 38.3 pg/mL (IQR, 41.0), p-value=0.024. In 
contrast, responders did not exhibit dynamic changes: 13.7 
pg/mL (IQR, 1.86) at baseline vs.12.6 pg/mL (IQR, 20.28) 
at 3 months, p-value=0.345. Similarly, baseline levels of 
sE-selectin decreased at 3 months in both responders and 
non-responders (p<0.001), but then increased at the end of 
the study (see Table 4). We observed other tendencies but 
dynamic differences could not be statistically confirmed 
for the remaining biomarkers during follow-up (see Table 
4); for instance, TIMP-1 levels were 30.5% lower in 
subjects with response versus 10.1% higher in patients 
who did not achieve response, p-value=0.21 (Figure 2D).
Median levels of proinflammatory cytokines (IL-6 
and IL-8), HGF, and OPN tended to be lower at the end 
of the study in individuals exhibiting tumor response in 
comparison with subjects with no response (see Figure 
2A, 2B, 2C & 2E). However, after adjusting for the 
family-wise error associated with multiple comparisons, 
none were significant (p-value >0.05 for all). In the case 
of IL-6, circulating levels remained all but undetectable in 
patients displaying tumor response throughout the entire 
follow-up period, with a baseline median of IL-6: 0 (IQR, 
2.22) vs. 4.5 pg/mL (IQR, 5.1), p-value=0.072 (see Figure 
2D). However, absolute levels of TIMP-1 and sE-Selectin 
were not significantly different at any point during follow-
up for subjects with or without response (see Figure 2A, 
2B, 2C  and 2D).
Finally, we analyzed whether the dynamic 
changes (reduction vs. increase) in each of the soluble 
markers exerted any effect on OS-related endpoints 
in addition to the Ki-67 index (see Supplementary 
Tables 4 & 6). Multiple comparison adjustments 
were not applied for time-to-event analyses, due to 
their exploratory purpose. Only IL-6 levels (pg/mL, 
continuous time-dependent variable) were significantly 
associated with increased mortality, with a HR of 
1.068 (CI 95%, 1.013-1.126), p-value=0.013. The 
effect was similar when restricted to baseline measures 
with HR 1.184 (CI 95%, 1.061-1.321), p-value=0.018. 
Similarly, OPN levels were associated with lower PFS, 
independent of the Ki67% index, with HR 1.087 (1.011-
1.169), p=0.023. Ki-67 expression was significantly 
associated with shorter both PFS and OS, as expected 
(see Supplementary Tables 3 & 5).
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DISCUSSION
This is a prospective, multicenter study of the effect 
of 14 SNPs and 6 circulating biomarkers on safety and 
efficacy endpoints in patients with low-grade PNETs (G1/
G2, WHO 2010) who received sunitinib. Basically, the 
work explores how these profiles modify the prognosis, 
and potentially influence differential response to this drug.
The reason for conducting this analysis was that 
certain key aspects of optimal selection of patients 
with a greater benefit-risk ratio have yet to be formally 
elucidated. In particular, the pivotal trial (SUN-1111) 
failed to report the analysis of subgroups based on genetic 
profiles or in-depth analyses of the evolution of circulating 
biomarkers according to response to sunitinib, which 
implied a lack of critical information both regarding key 
pharmacogenomic aspects of the therapy, as well as about 
the influence of tumor markers on tumor evolution [8].
The VEGFR-3 axis, through various signalling 
pathways, has a critical role in cancer progression by 
regulating different cellular functions such as angiogenesis, 
tumor growth, proliferation and chemotherapy resistance 
[14]. Neuroendocrine tumors are also highly dependent on 
VEGFR-3 signalling, which, in turn, is one of the most 
important targets of sunitinib [8]. Here, we have found 
that two missense mutations in VEGFR-3 (rs307826 and 
rs307821), present respectively in 34% and 26% of the 
participants in this study, are associated with decreased 
OS. VEGFR-3 c.1480A>G (rs307826) involves the 
exchange of a residue threonine for alanine, which is 
associated with a deficit of protein expression [15]. The 
modification of VEGFR-3 c.4202G>T (rs307821) is likely 
to have functional implications [9]. In both cases, these 
changes have previously been linked to decreased PFS in 
patients with PNETs, treated with pazopanib [16] or other 
drugs [17]. This has generally been attributed to resistance 
to tyrosine-kinase inhibitors [16, 18, 19].
Thus, Beuselinck’s renal cancer series reported 
that rs307826 affected survival outcomes with a median 
of 31 months of OS for genotype AA vs. 22 months for 
AG/GG variants (p=0.013) [18]. In contrast, García-
Donas et al. reported a series of 89 kidney cancer patients 
treated with sunitinib without any association with OS 
[9]. Our data also suggest that a SNP in the VEGFR-3 
gene (rs307821) increases the likelihood of developing 
hypothyroidism in patients treated with sunitinib. The 
biological mechanism of this correlation is not clear, 
although a tentative explanation could be the increased 
Table 2: Effect of polymorphisms on clinical benefit rate, PFS, and OS
Reference SNP 
ID
Clinical benefit PFS OS
OR (95% CI) p-value HR (95%, CI) p-value HR (95%, CI) p-value
VEGFR3
rs307826 1.43 (0.12-17.52) 0.782 1.31 (0.64-2.67) 0.464 3.67 (1.35-10) 0.010
rs307821 NC 0.999 1.04 (0.50-2.18) 0.917 3.84 (1.47- 10) 0.005
VEGFA
rs1570360 0.87 (0.07-10.93) 0.912 1.04 (0.49-2.50) 0.926 2.38 (0.83-7.14) 0.104
rs2010963 1.20 (0.09-15.09) 0.889 0.90 (0.44-1.85) 0.784 0.82 (0.32-2.12) 0.685
rs699947 0.21 (0.02-2.68) 0.230 1.14 (0.52-2.49) 0.745 1.02 (0.37-2.81) 0.962
IL-8 rs4073 0.87 (0.07-10.93) 0.912 1.04 (0.49-2.18) 0.926 2.38 (0.83-7.14) 0.104
FGFR2 rs2981582 NC 0.999 1.05 (0.46-2.40) 0.905 1.70 (0.58-4.98) 0.333
NR1|2 rs3814055 0.62 (0.05-7.57) 0.706 1.43 (0.70-2.91) 0.329 1.41 (0.57-3.51) 0.461
c-KIT rs6554199 1.20 (0.09-15.09) 0.889 0.90 (0.44-1.85) 0.784 0.82 (0.32-2.12) 0.685
PDGFB rs130650 NC 0.999 0.54 (0.25-1.15) 0.107 0.55 (0.21-1.40) 0.206
ABCB1
rs1045642 NC 0.999 1.85 (0.78-4.34) 0.162 2.12 (0.70-6.66) 0.174
rs1128503 1.51 (0.12-19.52) 0.750 0.92 (0.41-2.08) 0.842 0.78 (0.28-2.19) 0.642
rs2032582 1.24 (0.10-15.51) 0.869 0.90 (0.41-1.96) 0.790 0.72 (0.26-2.02) 0.536
CYP3A5 rs776746 NC 0.999 0.81 (0.34-1.92) 0.625 0.57 (0.16-2.0) 0.378
The comparison between homozygous wild-type genotype vs. other genotypes (used as a reference) are shown. 
Abbreviations: NC = not computable, PFS = progression-free survival, HR = hazard ratio, CI = confidence interval, OR = 
odds ratio, OS = overall survival. An OR<1 indicates that clinical benefit is less likely in subjects with the SNP. P-values 
are derived from bivariate binary logical regression for clinical benefit rate, and Cox proportional hazards regression for 
survival endpoints; adjusted by Ki67 index. Tests were not corrected for multiple comparisons. The clinical benefit rate is 
the sum of complete and partial responses and stable disease at 6 months.
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Figure 1: Kaplan-Meier analysis for OS in patients with rs307821. Abbreviations: OS = overall survival, HR = hazard ratio, CI 
= confidence interval.
Figure 2: Levels of circulating biomarkers at baseline, three months, and at the end of follow-up. (A) Interleukin-8 (IL-
8); (B) interleukin-6 (IL-6); (C) hepatocyte growth factor (HGF); (D) tissue inhibitor of metalloproteinase-1 (TIMP-1); (E) osteopontin 
(OPN) and (F) sE-selectinP-values are derived from U-Mann Whitney tests to compare differences between subjects who responded 
(Resp.) and those who did not respond to treatment (No resp.). Blood samples were available for baseline determinations in 36 patients (30 
non-responders, 6 responders); at three months in 31 patients (26 non-responders, 5 responders); and 27 subjects at the end of the study (22 
non-responders, 5 responders). Responders were those with complete or partial response; non-responders are those with tumor progression 
or stabilization at 3 months.
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vulnerability of the microvasculature of the thyroid gland 
to VEGFR2 inhibition when the VEGFR-3 signaling 
pathway is constitutively affected [20].
In line with previous research [21], our data also 
suggest how baseline levels and dynamic changes of 
soluble molecules implicated in alternative proangiogenic 
pathways, proinflammatory mechanisms, cell adhesion 
or migration (mainly IL-6, IL-8, and sE-selectin) vary 
differently according to the objective response to sunitinib. 
One of the most surprising outcomes is the verification 
that objective responses to sunitinib are accompanied 
by significantly lower or even undetectable levels of the 
proangiogenic cytokines IL-8 and IL-6, in line with data 
obtained in other cancers. In fact, IL-8 is a proangiogenic 
factor produced by tumor-infiltrating macrophages and 
other tissues, whose levels rise with exposure to sunitinib 
in several cancers, including PNETs [13, 22], which would 
appear to be part of a mechanism of drug resistance [23].
We have also found moderate statistical evidence 
that elevated OPN levels shortened PFS in this series. 
OPN is an extracellular protein that mediates interactions 
with integrins and components of the extracellular 
matrix, enhances angiogenesis by activating the PI3K/
AKT and ERK pathways [24, 25], which comprises a 
probable mechanism of acquired active resistance to 
antiangiogenics in several tumors [26].
Interestingly, we found that IL-6 constitutes an 
adverse prognostic factor [HR 1.068 (1.013-1.126)], 
independent of Ki67 index, which may actually help 
in the prognostic stratification of these tumors [27]. 
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The comparison between the dominant homozygous model and remaining genotypes (used as reference) is presented. The homozygous wild-type 
genotype is compared to the rest, referencing toxicities of any grade. P-values have been established based on Fisher’s exact tests for probability. 
Abbreviations: OR = odds ratio, CI = confidence interval.
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Our data support the finding that dynamic changes in 
other soluble molecules, such as sE-selectin, would also 
correlate with acquired resistance to sunitinib in PNETs 
and could be potential surrogate biomarkers of clinical 
benefit associated with antiangiogenic therapy in this 
neoplasm. sE-selectin plays a role in angiogenesis as an 
adhesion molecule and its effect is capable of modulating 
response to antiangiogenics, possibly through endothelial 
cell recruitment, and is a biomarker of VEGF-inhibiting 
therapies [28, 29].
Our data have limitations, and the reader must be 
aware that the findings of this hypothesis-generating study 
call for prospective validation with a larger sample. The 
absence of a comparator group precludes the assessment 
of interactions between SNPs and treatment effects. With 
the limited sample size, this study is underpowered and 
can hence best be considered as hypothesis-generating. 
As an example, the power to determine the increase of 
Il-8 between baseline and 3 months in the non-responders 
group by Wilcoxon Signed-Ranked Test is about 43%. 
When correction for multiple testing is applied for all 
correlations with the SNPs, none remain significant. 
However, the Holm–Bonferroni procedure is usually 
considered a relatively conservative method. As with other 
studies of SNPs, no pharmacokinetic data are available for 
sunitinib (or its metabolites) or for VEGF/VEGFR levels 
to correlate with each one of the genetic variants, though 
this endpoint would have been compelling. Moreover, 
concurrent use of SSA in 44% of patients may introduce 
an element of uncertainty into the assessment of PFS 
in this series [30]. Finally, the tumor itself has not been 
genotyped, which could certainly be informative, although 
other authors have found a high degree of concordance 
with the genetic profile of the germ line [31].
In conclusion, the exploratory SALSUN study 
points to an association between VEGFR-3 SNPs 
(rs307826 and rs307821) and various serum biomarkers 
(IL-6 and OPN) involved in alternative proangiogenic 
Table 4: Levels of biomarkers based on sensitivity to sunitinib





pg/mL Non-responders 28.56 (30.93) 38.37 (41.04) 39.45 (42.72) 0.002 (0.024) 0.001 (0.012)
Responders 13.73 (1.86) 12.63 (20.28) 10.74 (21.00) 0.345 (1) 0.224 (1)
IL-6,  
pg/mL Non-responders 4.55 (5.1) 3.33 (8.64) 0.75 (4.74) 0.180 (1) 0.064 (0.512)
Responders 0.00 (2.22) 0.00 (2.73) 0.00 (0.00) 0.296 (1) 0.317 (1)
HGF,  
pg/mL Non-responders 446.42 (346.38) 309.39 (450.09) 315.45 (266.22) 0.107 (0.967) 0.009 (0.099)
Responders 273.14 (254.01) 162.15 (22.02) 154.68 (74.40) 0.345 (1) 0.080 (0.480)
TIMP-1, 
ng/mL Non-responders 158.87 (215.97) 186.08 (193.94) 218.40 (254.65) 0.056 (0.560) 0.043 (0.430)
Responders 303.20 (154.32) 260.57 (125.60) 134.65 (179.40) 0.136 (1) 0.455 (0.910)
OPN,  
ng/mL Non-responders 34.36 (36.88) 40.90 (40.14) 38.57 (53.58) 0.253 (1) 0.654 (0.654)




Non-responders 56.83 (40.14) 36.95 (25.78) 60.92 (36.37) 0.003 (0.033) 0.064 (0.576)
Responders 56.03 (117.02) 24.52 (3.52) 64.09 (79.01) 0.068 (0.612) 0.068 (0.476)
Responders are those with complete or partial response; non-responders are those with tumor progression or stabilization 
at 6 months. Paired data were compared with the Wilcoxon Signed-Rank Test. The numbers for the “baseline”, “3 months” 
and “End of Study” columns represent the median, and the interquartile range (in brackets). ‡Raw p-values and p-values 
adjusted using the Bonferroni-Holm method (in brackets) for multiple comparisons are displayed. §Comparison between 
baseline and 3-month measures. §§Comparison between baseline and exit measures. Abbreviations: IL-6 = interleukin-6, 
IL-8 = interleukin-8, HGF = hepatocyte growth factor, TIMP-1 = tissue inhibitor of metalloproteinase-1, and OPN = 
osteopontin.
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pathways and mechanisms of resistance, and clinical 
outcomes during the course of therapy with sunitinib, 
and might serve as surrogate endpoints in future clinical 
trials in PNETs. The search for individualized treatment 
algorithms should be promoted based on genetic variants 




We have conducted a prospective phase IV study, 
in 11 Spanish hospitals. All adult patients (≥18 years) 
with a histological diagnosis of well- or moderately-
differentiated (Ki-67 ≤20%) metastatic PNET, scheduled 
to begin treatment with sunitinib as per clinical practice 
at each center were consecutively enrolled. Other 
eligibility criteria included the presence of measurable 
tumor disease by Response Evaluation Criteria In 
Solid Tumors (RECIST) 1.1 criteria, with confirmed 
radiological progression in the previous 12 months and 
adequate hematological, hepatic, and renal function. 
Subjects had to have an Eastern Cooperative Oncology 
Group performance status (ECOG-PS) of 0-1 and could 
not have received prior treatment with mTOR inhibitors 
or antiangiogenic agents. Likewise, those individuals with 
symptomatic brain metastases, prior cardiac events or 
thromboembolic disease in the previous 12 months were 
excluded. The study was approved by the Ethic Committee 
of the Salamanca University Hospital, and all participants 
provided written informed consent.
Procedures
Treatment procedures and clinical decisions, 
including dose reduction policy or management of 
toxicities, were made by the investigators according to 
each center’s clinical practice. Histopathological and 
clinical data were collected with an electronic case report 
form and were regularly monitored externally to guarantee 
both the quality and safety of the process.
Molecular analyses were performed centrally 
at two different laboratories, blinded as to clinical or 
evolutionary data. Fourteen SNPs in 9 genes involved 
in the pharmacodynamic mechanism, metabolism and 
detoxification of sunitinib, were evaluated. These SNPs 
are located in genes that code for cytokines and tyrosine 
kinase receptors: VEGFR-3 (rs307826, rs307821), 
VEGFA (rs1570360; rs699947, rs2010963), interleukin-8 
(IL-8) (rs4073), FGFR2 (rs2981582), c-KIT (rs6554199), 
PDGFB (rs3814055) [9, 10], as well as in genes that 
participate in cell detoxification and drug metabolism: 
ABCB1 (rs1045642, rs1128503, rs2032582), NR1I2 
(rs3814055) and CYP3A5 (rs776746) [9, 10]. These SNPs 
were chosen following a review of the literature based on: 
the presence of prior evidence of their association with 
PFS/OS during treatment with sunitinib or pazopanib, 
that entailed a switch in the sequence of amino acids and 
that had minor allele frequencies ≥5% in previous studies 
[10–18]. With respect to the genes of angiogenesis, we 
focused on VEGFR-3 because the preclinical evidence 
suggests that it has a more active role than VEGFR-2 
in the development of distant and lymphatic metastases 
[9]. DNA was isolated from peripheral blood by standard 
proteinase K and phenol-chloroform protocols. Blood was 
stored at -20°C until analysis. Genotyping was performed 
with Real-Time PCR and TaqMan SNP genotyping assays, 
using the StepOnePlus® System to detect fluorescence and 
assign alleles (Applied Biosystems; Foster City, CA).
Simultaneously, hepatocyte growth factor 
(HGF), interleukin-6 (IL-6), IL-8, tissue inhibitor 
of metalloproteinase-1 (TIMP-1), sE-selectin, and 
osteopontin (OPN) levels were determined in patients’ 
blood samples. These molecules were chosen for their 
putative role in the angiogenic process and/or earlier 
evidence of sunitinib’s effect on their circulating levels 
[32]. Biomarker levels were quantified by the multiplex 
bead assays (Luminex xMAP) incorporated into the 
MILLIPLEX MAP kits and run on Luminex 200, 
according to the manufacturer’s instructions. Samples 
were drawn at baseline, three months and at the time of 
patient progression.
Objectives & variables
We conducted a hypothesis-generating pilot study 
to correlate the presence of the afore-named SNPs and 
the trend of circulating biomarkers in responders and 
non-responders to sunitinib. Other exploratory objectives 
included establishing the correlation with clinical benefit 
and objective response rates, survival-based endpoints 
(PFS/OS), overall toxicity, class-specific toxicities, and 
dose reductions due to toxicity. OS was defined as the 
time elapsed between initiating therapy with sunitinib 
and the date of death due to any cause, whereas PFS was 
considered to be the time between treatment initiation 
until objective progression or demise. In any case, 
subjects with no event at the end of follow-up were 
censored. Objective response was evaluated locally by 
the researchers using RECIST 1.1 every 6 months until 
progression or withdrawal from the study [33]. Response 
was not centrally assessed. The rate of clinical benefit 
was defined as the sum of evaluations with complete 
or partial response, and stable disease. Adverse events 
were graded as per the Common Terminology Criteria 
for Adverse Events (CTCAE), version 3.0 [34]. Since 
the genotypes identified with homozygous variants were 
uncommon, we pooled these cases with heterozygous 
genotypes in the survival analysis. Tumors have been 




Hardy-Weinberg equilibrium (HWE) assumption 
was calculated by Chi-squared test for each SNP. The 
association between clinical and molecular variables 
was analyzed by crosstabs and Pearson’s chi-squared 
tests (χ2), while odds ratio (OR) and 95% confident 
intervals were calculated by logistic regression 
analyses. OS and PFS-related endpoints were estimated 
using the Kaplan-Meier method. To evaluate the effect 
of each SNP for each OS endpoint, Cox’s proportional 
hazards (PH) regression was used, adjusted by Ki67 
index. Cytokines and serum biomarkers were treated 
as time-dependent variables [36]. Fisher’s exact 
test was applied to compare categorical variables. 
Statistical hypothesis testing for continuous variables 
was performed using the Mann-Whitney U test (due 
to the non-normality of these variables). Paired data 
were compared with the Wilcoxon Signed-Rank 
Test. All statistical assessments were two-sided and 
p-values<0.05 were deemed significant. Given the 
exploratory nature of the study in a field for which no 
published data were available during the design phase, 
no statistical tool was applied to calculate sample 
size. Furthermore, for the same reason, corrections 
for multiple comparison were performed only for the 
effect of circulating biomarkers on response. The SPSS 
version 19.0 statistical software package was used.
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